Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. It is also involved in holding Litecoin tokens as a primary reserve asset. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.…
Litecoin Just Turned 15. Has It Kept Up With Bitcoin?
Lite Strategy (NASDAQ: LITS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 5 employees.
The shares were at 0.8026 USD on 20 November 2026, down 61.8% over 52 weeks. Its 52-week range is 0.6888 USD to 2.260 USD: the price is 64.5% below the high and 16.5% above the low.
Its market capitalisation is 23.99M USD.
Lite Strategy reports return on equity of -170.9% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 4.28M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 16 February 2027.